GlobeNewswire by notified

Mendus AB Interim Report January – September 2023


Press Release

Stockholm, Sweden, November 9, 2023

So far in 2023, Mendus has realized significant progress in its corporate development, and we aim to end the year strong

The progress made in the previous quarters provided the basis for a financing round which we completed in July, to support the next stage of our corporate development. The directed placement and rights issue totaling SEK 317M supports further read-outs of the ongoing ADVANCE II and ALISON vididencel trials, the start of new clinical trials with vididencel and ilixadencel and progressing our preclinical pipeline. Additionally, Mendus has entered into a manufacturing alliance with NorthX Biologics, to support large-scale manufacturing of its lead product candidate vididencel. The regulatory status of vididencel was strengthened in Q3 by the Fast Track Designation granted by the US FDA.

The main milestone ahead of us in the fourth quarter of 2023 is the next read-out of the patient survival data in the ADVANCE II trial, which studies vididencel as a maintenance therapy for acute myeloid leukemia (AML). The data will be presented as an oral presentation at the 65th American Society of Hematology conference (ASH 2023), the largest and most significant hematology conference in the world, to be held December 9-12 in San Diego. It will be the third time Mendus presents the ADVANCE II trial data as an oral presentation at ASH, which underscores the high interest in vididencel as a potential novel AML maintenance treatment by the medical specialist community.

The ADVANCE II trial is a Phase 2 monotherapy trial addressing AML patients in complete remission, but with measurable residual disease (MRD), which is associated with fast relapse and, as a result, strongly reduced overall survival. The ADVANCE II data presented last year at ASH 2022, revealed that the majority of patients were not only alive at the end of the 70-week study period, but also remained alive and disease-free in long-term follow up ranging from 16 to 47 months. The monotherapy survival data, combined with an excellent safety profile, strongly support the development of vididencel as a novel maintenance treatment in AML. The next data read-out to be presented at ASH 2023 will provide an update on both relapse-free and overall survival.

The ADVANCE II trial is reinforced by immunomonitoring studies, which document the effect of vididencel on the immune system. Immunomonitoring data demonstrating the boosting of broad and robust immune responses were presented at leading scientific conferences, including the International Cancer Immunotherapy Conference (CICON) in September. At ASH 2023, next to the oral presentation of the survival data, we and our scientific partners at different academic hospitals will present two additional abstracts, which describe in detail the immune responses observed in the skin and in the blood following intradermal injection of vididencel, supporting its mode of action.

As a next step in the development of vididencel, Mendus is preparing for a combination trial of vididencel with oral azacitidine (oral AZA), currently the only approved AML maintenance drug). Together with the ADVANCE II monotherapy data, the Phase 2 combination trial with oral AZA will be a step up towards pivotal-stage development of vididencel in the AML maintenance setting. Mendus expects to announce details and start of the trial before year-end 2023.

In Q3, Mendus has taken the first steps in implementing the manufacturing alliance with NorthX Biologics, a leading Nordic contract development and manufacturing organization for cell and gene therapies. Large-scale, commercial-grade manufacturing is an important step for late-stage clinical development of vididencel and NorthX will therefore be a significant partner for Mendus going forward.

In September, the US FDA granted Fast Track Designation for the development of vididencel as an AML maintenance therapy, adding substantial regulatory value to the program in the most important healthcare market worldwide. The development of vididencel towards market registration in AML is also supported by Orphan Drug status in the EU and US and the vididencel manufacturing process and regulatory dossier has been validated by an EMA Advanced Therapy Medicinal Products (ATMP) certificate.

Data from the Phase 1 ALISON trial studying vididencel as a maintenance therapy in ovarian cancer were presented at the American Association for Cancer Research (AACR) conference held in April 2023 and the Society for Immunotherapy of Cancer (SITC) conference early November. The data confirmed the benign safety profile and potential of vididencel to stimulate immune responses against tumor antigens previously shown to be relevant for ovarian cancer. Recruitment of the ALISON trial (n = 17) is nearly complete with 16 patients having entered the trial and is expected to close before year-end 2023. Next read-outs of the ALISON trial are expected in the first half of 2024.

Following a series of manufacturing process improvements, Mendus’ second clinical-stage program ilixadencel is ready to be tested in a proof-of- concept trial based on initial positive data observed in gastrointestinal stromal tumors (GIST). There is continued clinical interest in pursuing a trial with ilixadencel in soft-tissue sarcomas, of which GIST is a subtype. The trial is expected to commence before year-end 2023. In Q3, Mendus announced the publication of preclinical data supporting the combination of ilixadencel with 4-1BB checkpoint modulators in a peer-reviewed journal.

In 2023, Mendus has so far realized significant progress in its corporate development, and we aim to end the year strong, based on the next ADVANCE II update at ASH, the start of a vididencel combination trial with oral AZA, the shaping of our alliance with NorthX Biologics and additional clinical milestones. We look forward to keeping our shareholders informed of our progress and thank you for your continued support.

Erik Manting, Ph.D.

Chief Executive Officer


  • Net sales for the period amounted to KSEK - (-)
  • Result for the period amounted to KSEK -26,400 (-38,605)
  • Earnings and diluted earnings per share totaled SEK -0,05 (-0,19)
  • At an extraordinary general meeting in Mendus AB, on 10 July 2023, the meeting resolved in accordance with the board of directors’ proposal to amend the articles of association with respect to the Company’s limits for the share capital and the number of shares. Furthermore, the AGM approved the issue of shares and warrants (units) with preferential rights for existing shareholders.
  • Mendus publishes prospectus regarding previously announced rights issue and directed issue
  • Mendus reports outcome of previously announced rights issue and directed issue
  • Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies
  • Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)
  • Mendus presents novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23


  • Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data
  • Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients is published in peer-reviewed medical journal
  • Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023


KSEK unless otherwise statedJul - SepJul - SepJan - SepJan - SepFull year
Operating profit/loss-25 855-37 403-57 930-92 356-133 957
Net profit/loss-26 400-38 605-60 454-95 505-138 786
Earnings/loss per share, before and after dilution (SEK)-0,05-0,19-0,18-0,48-0,70
Cash143 35055 403143 35055 40341 851
Shareholders equity751 135561 151751 135561 151514 439
Number of employees2631263131


The company will hold a conference call and webcast presentation on the same day at 10.00am CET, to provide an update on the latest developments and the outlook for the remainder of the year.

The webcast will be webcasted live via the link:

The full report is attached as PDF and is available on the company’s website:


Erik Manting, CEO



Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release

Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu

Havila Kystruten AS: Regnskap for tredje kvartal 20231.12.2023 18:34:33 CET | Pressemelding

September var første måned med full drift av alle fire skip. Til tross for forsinkelse av Havila Polaris og Havila Pollux i Q3, ble gjennomsnittlig belegg 70 % og gjennomsnittlig lugarrate kr 4 466. Inntektene er naturligvis preget av forsinkelsene og lavere enn forventet, men selskapet ser en positiv inntektsutvikling fra 2. kvartal og videre ut året. I forbindelse med refinansiering er driftskostnadene påvirket av ekstraordinære kostnader knyttet til juridiske og finansielle rådgivere. Regnskap og balanse påvirkes av valutasvingningene, og selskapet sikrer sine valutaforpliktelser med salg i valuta. Selskapet legger til grunn en normalisert drift av fire skip fremover, uten ekstraordinære kostnader. Selskapet har ambisjoner om et gjennomsnittlig belegg på 80 % for 2024, hvorav 45 % av all kapasitet allerede er solgt. Interessen for Havila Kystruten øker stadig i både inn- og utland, og positive tilbakemeldinger om produkt og konsept mottas på daglig basis. Resultat for 3. kvartal 202

Havila Kystruten : Third quarter 2023 accounts1.12.2023 18:34:33 CET | Press release

September marked the first month of full operation for all four ships. Despite the delays with Havila Polaris and Havila Pollux in Q3, the average occupancy rate reached 70%, with an average cabin rate of NOK 4,466. Revenues are naturally affected by the delays and lower than expected, but the company sees a positive revenue trend from the 2nd quarter and onward throughout the year. In connection with refinancing, operating costs were affected by extraordinary expenses related to legal and financial advisors. Currency fluctuations have had an impact on the financial statements and balance sheet, and the company is hedging its currency commitments through currency sales. The company assumes normalized operation of four ships going forward, without extraordinary costs. The company aims for an average occupancy rate of 80% for 2024, with 45% of all capacity already sold. Interest in Havila Kystruten is continually growing both domestically and internationally, with positive feedback on th

Resultat af aktietilbagekøb1.12.2023 17:41:01 CET | pressemeddelelse

Selskabet meddelte i selskabsmeddelelse 30/2023, at man havde besluttet at iværksætte et aktietilbagekøb på køb af optil 1.000.000 aktier til kurs 2.50 svarende til maksimalt DKK 2.5 mio. i perioden 22. november – 1. december 2023, begge dage inklusive. I hele perioden har der været indlagt en synlig stående budordrer i kurs 2.50, så markedet løbende har kunne følge tilbagekøbets udvikling, og som det også fremgik af selskabsmeddelelse 30/2023, så stod alle insidere tilbage for selskabets aktionærer, så insidere som ønskede at sælge aktier kun kunne tilbagesælge aktier den sidste dag, dvs. fra og med fredag d. 1. december 2023 kl. 09.00. Resultatet af insidernes evt. frasalg vil fremgå af en separat meddelelse. Resultatet af aktietilbagekøbsprogrammet blev at selskabet har tilbagekøbt 19.687 aktier til kurs 2.50 svarende til DKK 49.217,50. Selskabet ejer pr. dags dato totalt 4.854.063 egne aktier svarende til 9,06 % af selskabets aktiekapital. Det samlede antal aktier i virksomheden er

Registration of share capital increase in IDEX Biometrics 1 Dec 20231.12.2023 17:30:00 CET | Press release

Reference is made to the notice on 21 November 2023 regarding employees having exercised 389,608 incentive subscription rights at NOK 0.15 per share. The capital increase has been registered and the shares will be delivered soonest. Following the issue, the company's share capital is NOK 209,551,597.20 divided into 1,397,010,648 shares, each with a nominal value of NOK 0.15. For further information contact: Marianne Bøe, Investor Relations E-mail: Tel: +47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As